ArticleJournal of acquired immune deficiency syndromes (1999)2010
Antiretroviral treatment 2010: progress and controversies.
Article in Journal of acquired immune deficiency syndromes (1999), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Temporal shifts in antiretroviral therapy regimens and metabolic outcomes in people living with HIV: A systematic review and meta-analysis.HIV medicine · 2026Pooled it
- Non-Adherence to Anti-Retroviral Therapy Among Adult People Living with HIV in Ethiopia: Systematic Review and Meta-Analysis.AIDS and behavior · 2024Pooled it
- Critical Care Pharmacology of Antiretroviral Therapy in Adults.European journal of drug metabolism and pharmacokinetics · 2025Review
- Factors contributing to antiretroviral drug adherence among adults living with HIV or AIDS in a Kenyan rural community.African journal of primary health care & family medicine · 2017Article
- Applying evolutionary biology to address global challenges.Science (New York, N.Y.) · 2014Review
- DNA sequencing and bar-coding using solid-state nanopores.Electrophoresis · 2012Review
- National and international policies to mitigate disease threats.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2012Article
- Translational research in infectious disease: current paradigms and challenges ahead.Translational research : the journal of laboratory and clinical medicine · 2012Review
- Review
- Medication-related barriers to entering HIV care.AIDS patient care and STDs · 2012Article
- Use of and Adherence to Antiretroviral Therapy in a Large U.S. Sample of HIV-infected Adults in Care, 2007-2008.The open AIDS journal · 2012Article
- Complications of common gynecologic surgeries among HIV-infected women in the United States.Infectious diseases in obstetrics and gynecology · 2012Article
- Prevention and treatment of HIV/AIDS among drug-using populations: a global perspective.Journal of acquired immune deficiency syndromes (1999) · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Effective antiretroviral therapy (ART) changes the clinical course of HIV infection. There are 25 antiretroviral drugs approved for the treatment of HIV infection, and current antiretroviral drug regimens are highly effective, convenient, and relatively nontoxic. ART regimens should be chosen in consideration of a patient's particular clinical situation. Successful treatment is associated with durable suppression of HIV viremia over years, and consequently, ART reduces the risk of clinical progression. In fact, current models estimate that an HIV-infected individual appropriately treated with antiretroviral drugs has a life expectancy that approaches that of the general HIV-uninfected population, although some patient groups such as injection drug users do less well. Despite these advances, continued questions about ART persist: What is the optimal time to start ART? What is the best regimen to start? When is the optimal time to change ART? What is the best regimen to change to? In addition, newer antiretroviral agents are in development, both in existing classes and in new classes such as the CD4 receptor attachment inhibitors and the maturation inhibitors. Further research will help optimize current antiretroviral treatments and strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.